BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach

被引：1
作者：
Menger, Jenna M. [1 ]
Sathianathen, Ryan S. [2 ]
Sakamoto, Kathleen M. [3 ]
Hijiya, Nobuko [1 ]
机构：
[1] Columbia Univ, Dept Pediat, Div Pediat Hematol Oncol Stem Cell Transplant, Irving Med Ctr, New York, NY 10069 USA
[2] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Pediat, Div Hematol Oncol, Stanford, CA 94305 USA
来源：
CURRENT ONCOLOGY REPORTS | 2024年 / 26卷 / 03期
关键词：
Pediatric cancer; Chronic myeloid leukemia; CML; Tyrosine kinase inhibitor; TKI; BCR-ABL1; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITORS; OMACETAXINE MEPESUCCINATE; IMATINIB; PHASE; SURVIVAL; THERAPY; CML; DASATINIB; NILOTINIB;
D O I：
10.1007/s11912-024-01502-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose of ReviewThe purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current areas of investigation.Recent FindingsThere is new phase 1 data to support the safety of the non-ATP competitive tyrosine kinase inhibitor (TKI) asciminib in the pediatric cohort. Ongoing studies are investigating the role of treatment-free remission in children.SummaryChronic phase CML in children is managed with lifelong TKI therapy; however, evidence of deeper remissions sustained with second-generation TKIs may permit shorter treatment courses. Use of more specific TKIs may mitigate some of the side effects specific to the pediatric cohort. Children with advanced phase CML should achieve a complete hematologic remission with use of a second-generation TKI prior to transplant to achieve the best outcome.
引用
收藏
页码：250 / 257
页数：8
相关论文
共 50 条
[31]   Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence [J].
Ciftciler, R. ;
Haznedaroglu, I. C. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (24) :7787-7798
[32]   Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia [J].
Luis Steegmann, Juan ;
Cervantes, Francisco ;
le Coutre, Philipp ;
Porkka, Kimmo ;
Saglio, Giuseppe .
LEUKEMIA & LYMPHOMA, 2012, 53 (12) :2351-2361
[33]   BCR-ABL Mutations in Chronic Myeloid Leukemia [J].
Ernst, Thomas ;
La Rosee, Paul ;
Mueller, Martin C. ;
Hochhaus, Andreas .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (05) :997-+
[34]   BCR-ABL-negative chronic myeloid leukemia [J].
Burgstaller S. ;
Reiter A. ;
Cross N.C.P. .
Current Hematologic Malignancy Reports, 2007, 2 (2) :75-82
[35]   Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis [J].
Soverini, Simona ;
Martinelli, Giovanni ;
Rosti, Gianantonio ;
Iacobucci, Ilaria ;
Baccarani, Michele .
PHARMACOGENOMICS, 2012, 13 (11) :1271-1284
[36]   Successful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and BCR-ABL1-Positive Chronic Myeloid Leukemia: A Case Report [J].
Tsukaguchi, Akihiro ;
Minami, Seigo ;
Yasuoka, Hironao ;
Kin, Yoshihiro .
CASE REPORTS IN ONCOLOGY, 2022, 15 (03) :1081-1087
[37]   Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms? [J].
Yap, E. ;
Tumian, N. R. ;
Azma, R. Z. ;
Sharifah, N. A. ;
Salwati, S. ;
Hamidah, N. H. ;
Elias, M. H. ;
Wong, C. L. .
MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) :107-113
[38]   BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients [J].
le Coutre, Philipp ;
Reinke, Petra ;
Neuhaus, Ruth ;
Trappe, Ralf ;
Ringel, Frauke ;
Lalancette, Marc ;
Hemmati, Philipp G. ;
Doerken, Bernd ;
Daniel, Peter T. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (01) :26-33
[39]   Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia [J].
Parcha, Phanikrishna ;
Sarvagalla, Sailu ;
Madhuri, Bindu ;
Pajaniradje, Sankar ;
Baskaran, Vinitha ;
Coumar, Mohane Selvaraj ;
Rajasekaran, Baskaran .
CHEMICAL BIOLOGY & DRUG DESIGN, 2017, 90 (04) :596-608
[40]   Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia [J].
Lee, Hyewon ;
Basso, Igor Novitzky ;
Kim, Dennis Dong Hwan .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (05) :632-641
12345